search
Back to results

Performance Evaluation of the LumiraDx SARS-CoV-2 & FLU A/B and SARS-CoV-2 & RSV Tests for Aid in the Assessment of COVID-19 (INSPIRE-2)

Primary Purpose

COVID-19, Influenza A, Influenza Type B

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
LumiraDx SARS-CoV-2 & Flu A/B test
LumiraDx SARS-CoV-2 & RSV test
Sponsored by
LumiraDx UK Limited
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for COVID-19

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Preliminary assessment of the subject by the Investigator/designee should be suggestive of COVID-19 and /or influenza and/or RSV at the time of the study visit.
  2. The subject must present in one of the following two cohorts:

    Covid Cohort:

    Preliminary assessment of the subject by the Investigator/designee should be suggestive of COVID-19 at the time of the study visit. The subject must present as symptomatic, meaning they have exhibited one or more of the following signs and symptoms for eligibility: fever, cough, shortness of breath, difficulty breathing, muscle pain, headache, sore throat, chills, repeated shaking with chills, new loss of taste or smell, congestion or runny nose, diarrhea, nausea or vomiting. The onset of these symptoms will be recorded and will be in the last twelve (12) days.

    or The subject must have presented with respiratory symptoms and a documented positive SARS-CoV-2 PCR or antigen test in the past forty-eight (48) hours.

    Influenza/RSV Cohort:

    The subject must have a fever of 100.0 °F or greater with the onset of the fever being within the past three (3) days and/or present at the time of the visit. Fever can be reported or taken at time of visit. Subjects must report having a fever, but a quantitative reported measurement is not necessary for inclusion. In addition to the fever, the subject must have two (2) or more of the following signs and symptoms for eligibility: cough, shortness of breath, difficulty breathing, muscle pain, joint pain, headache, chills, repeated shaking with chills, congestion or runny nose, diarrhea, nausea, vomiting, sneezing, sore throat, wheezing, fatigue, weakness and/or malaise or anorexia. The onset of these symptoms will be recorded and will be in the last four (4) days. OR The subject must have presented with respiratory symptoms and a documented positive Flu or RSV test in the past forty-eight (48) hours.

  3. Written informed consent must be obtained prior to study enrollment. A subject who is a legal adult must be willing to give written informed consent and must agree to comply with study procedures. The Legal Guardian or Legal Authorized Representative of a subject who is under the age of consent must give written informed consent and agree to comply with study procedures. Active assent should be obtained from children of appropriate intellectual age (as defined by the IRB)

Exclusion Criteria:

  1. The subject underwent a nasal wash/aspirate as part of standard of care testing during this study visit.
  2. Subjects undergoing treatment currently and/or within the past fourteen (14 days of the study visit with an inhaled influenza vaccine (FluMist®) or with antiviral medication, which may include but is not limited to Amantadine (Symmetrel®), Rimantadine (Flumadine®), Zanamivir (Relenza®), Oseltamivir (Tamiflu®), or Baloxavir Marboxil (Xofluza™)
  3. Subjects undergoing treatment currently and/or within the past thirty (30) days of the study with prescription medication to treat novel Coronavirus SARS-CoV-2 infection, which may include but is not limited to Remdesivir (Veklury) or receiving convalescent plasma therapy for SARS-CoV-2;
  4. The subject is undergoing treatment currently or had undergone within the past fourteen (14) days of the study visit with RSV-related medication which may include but is not limited to Ribavirin (Virazole), RSV-IGIV (RespiGam) or palivizumab (Synagis).
  5. The subject is currently receiving or has received within the past thirty (30) days of the study visit an experimental biologic, drug, or device including either treatment or therapy.
  6. The subject has previously participated in this research study (CS-1262-01).

Sites / Locations

  • Cullman Clinical Trials
  • Diagnamics, Inc
  • Excellence Medical and Research
  • Marisela Gonzalez, MD, PA
  • Koch Family Medicine
  • Benchmark Research
  • Machuca Foundation
  • Clinical Research Solutions

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Nasal Swab

Nasopharyngeal Swab

Arm Description

Nasal swab from subjects with signs and symptoms of COVID-19 and/or Influenza and/or RSV-like illness

Nasopharyngeal swab from subjects with signs and symptoms of COVID-19 and/or Influenza and/or RSV-like illness

Outcomes

Primary Outcome Measures

Performance evaluation by health care professionals
Evaluate the performance of the LumiraDx Tests in detecting and differentiating SARS-CoV-2, influenza A, influenza B and/or RSV in fresh nasal or nasopharyngeal swab specimens from patients with signs and symptoms of COVID-19, Influenza and/or RSV-like illness. Performance will be evaluated by use of statistical analysis techniques to assess sensitivity (true positive rate), specificity (true negative rate), Negative and Positive Percent Agreement (NPA, PPA) of the LumiraDx test results versus an FDA-approved method where a result of 100% sensitivity, specificity, NPA or PPA would equate to complete agreement with the reference method and 0% would equate to no agreement.
Point of Care usability
Evaluate the point of care usability of the LumiraDx SARS-CoV-2 & Flu A/B Test and LumiraDx SARS-CoV-2 & RSV Tests. Usability will be assessed by means of a user questionnaire to be completed by naive users following their first test of the devices using standard Pack Leaflet and Quick Reference Instructions.

Secondary Outcome Measures

Full Information

First Posted
March 3, 2022
Last Updated
August 11, 2023
Sponsor
LumiraDx UK Limited
search

1. Study Identification

Unique Protocol Identification Number
NCT05268939
Brief Title
Performance Evaluation of the LumiraDx SARS-CoV-2 & FLU A/B and SARS-CoV-2 & RSV Tests for Aid in the Assessment of COVID-19
Acronym
INSPIRE-2
Official Title
A Multicenter Study Conducted to Evaluate the Performance of the LumiraDx SARS-CoV-2 & FLU A/B Test, and LumiraDx SARS-CoV-2 & RSV Test at Point of Care Testing Sites
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Completed
Study Start Date
January 4, 2022 (Actual)
Primary Completion Date
April 25, 2022 (Actual)
Study Completion Date
March 14, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
LumiraDx UK Limited

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Device Product Not Approved or Cleared by U.S. FDA
Yes
Product Manufactured in and Exported from the U.S.
No

5. Study Description

Brief Summary
A Multicenter Study Conducted to Evaluate the Performance of the LumiraDx SARS-CoV-2 & FLU A/B Test, and LumiraDx SARS-CoV-2 & RSV Test at Point of Care Testing Sites. Subjects presenting with symptoms suggestive of COVID-19 and/or Influenza and/or RSV will be consented and asked to donate swab sample(s) for testing in the device(s) under evaluation.
Detailed Description
Approximately one-thousand (1000) subjects will be enrolled in this study. Patients presenting to their health care professionals, drive through testing sites or research centers and meet the inclusion/exclusion criteria will be enrolled in the study. A subject's participation in this study will consist of a single visit. Following completion of the informed consent process and a review of Inclusion/Exclusion criteria to determine eligibility, each subject will receive a unique study identification number. The potential subject will be asked to provide relevant medical history information (i.e., regarding their influenza/RSV and or COVID-19-like symptoms), which will be evaluated against all inclusion and exclusion criteria depending in their cohort. A subject's SARS-CoV-2 vaccination status will also be collected including the doses, dates of vaccination and brand. Specimens will be obtained from each subject enrolled using standard collection methods. The objectives of this study are to: Evaluate the performance of the LumiraDx SARS-CoV-2 & Flu A/B Test in detecting SARS-CoV-2 and/ or influenza A or B in nasal and nasopharyngeal swabs from patients with signs and symptoms of COVID-19 or influenza as compared with an FDA EUA authorized or 510(k) comparative method. Evaluate the performance of the LumiraDx SARS-CoV-2 & RSV Test in detecting SARS-CoV-2 and/ or RSV in nasal and nasopharyngeal swabs from patients with signs and symptoms of COVID-19 or RSV as compared with an FDA EUA authorized or 510(k) comparative method. Evaluate the point of care usability of the LumiraDx SARS-CoV-2 & Flu A/B Test and LumiraDx SARS-CoV-2 & RSV Test.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
COVID-19, Influenza A, Influenza Type B, RSV Infection

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
Performance Evaluation study
Masking
None (Open Label)
Allocation
Randomized
Enrollment
668 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Nasal Swab
Arm Type
Experimental
Arm Description
Nasal swab from subjects with signs and symptoms of COVID-19 and/or Influenza and/or RSV-like illness
Arm Title
Nasopharyngeal Swab
Arm Type
Experimental
Arm Description
Nasopharyngeal swab from subjects with signs and symptoms of COVID-19 and/or Influenza and/or RSV-like illness
Intervention Type
Diagnostic Test
Intervention Name(s)
LumiraDx SARS-CoV-2 & Flu A/B test
Intervention Description
Swab Samples for Diagnostic test
Intervention Type
Diagnostic Test
Intervention Name(s)
LumiraDx SARS-CoV-2 & RSV test
Intervention Description
Swab Samples for Diagnostic test
Primary Outcome Measure Information:
Title
Performance evaluation by health care professionals
Description
Evaluate the performance of the LumiraDx Tests in detecting and differentiating SARS-CoV-2, influenza A, influenza B and/or RSV in fresh nasal or nasopharyngeal swab specimens from patients with signs and symptoms of COVID-19, Influenza and/or RSV-like illness. Performance will be evaluated by use of statistical analysis techniques to assess sensitivity (true positive rate), specificity (true negative rate), Negative and Positive Percent Agreement (NPA, PPA) of the LumiraDx test results versus an FDA-approved method where a result of 100% sensitivity, specificity, NPA or PPA would equate to complete agreement with the reference method and 0% would equate to no agreement.
Time Frame
4 months
Title
Point of Care usability
Description
Evaluate the point of care usability of the LumiraDx SARS-CoV-2 & Flu A/B Test and LumiraDx SARS-CoV-2 & RSV Tests. Usability will be assessed by means of a user questionnaire to be completed by naive users following their first test of the devices using standard Pack Leaflet and Quick Reference Instructions.
Time Frame
4 months

10. Eligibility

Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Preliminary assessment of the subject by the Investigator/designee should be suggestive of COVID-19 and /or influenza and/or RSV at the time of the study visit. The subject must present in one of the following two cohorts: Covid Cohort: Preliminary assessment of the subject by the Investigator/designee should be suggestive of COVID-19 at the time of the study visit. The subject must present as symptomatic, meaning they have exhibited one or more of the following signs and symptoms for eligibility: fever, cough, shortness of breath, difficulty breathing, muscle pain, headache, sore throat, chills, repeated shaking with chills, new loss of taste or smell, congestion or runny nose, diarrhea, nausea or vomiting. The onset of these symptoms will be recorded and will be in the last twelve (12) days. or The subject must have presented with respiratory symptoms and a documented positive SARS-CoV-2 PCR or antigen test in the past forty-eight (48) hours. Influenza/RSV Cohort: The subject must have a fever of 100.0 °F or greater with the onset of the fever being within the past three (3) days and/or present at the time of the visit. Fever can be reported or taken at time of visit. Subjects must report having a fever, but a quantitative reported measurement is not necessary for inclusion. In addition to the fever, the subject must have two (2) or more of the following signs and symptoms for eligibility: cough, shortness of breath, difficulty breathing, muscle pain, joint pain, headache, chills, repeated shaking with chills, congestion or runny nose, diarrhea, nausea, vomiting, sneezing, sore throat, wheezing, fatigue, weakness and/or malaise or anorexia. The onset of these symptoms will be recorded and will be in the last four (4) days. OR The subject must have presented with respiratory symptoms and a documented positive Flu or RSV test in the past forty-eight (48) hours. Written informed consent must be obtained prior to study enrollment. A subject who is a legal adult must be willing to give written informed consent and must agree to comply with study procedures. The Legal Guardian or Legal Authorized Representative of a subject who is under the age of consent must give written informed consent and agree to comply with study procedures. Active assent should be obtained from children of appropriate intellectual age (as defined by the IRB) Exclusion Criteria: The subject underwent a nasal wash/aspirate as part of standard of care testing during this study visit. Subjects undergoing treatment currently and/or within the past fourteen (14 days of the study visit with an inhaled influenza vaccine (FluMist®) or with antiviral medication, which may include but is not limited to Amantadine (Symmetrel®), Rimantadine (Flumadine®), Zanamivir (Relenza®), Oseltamivir (Tamiflu®), or Baloxavir Marboxil (Xofluza™) Subjects undergoing treatment currently and/or within the past thirty (30) days of the study with prescription medication to treat novel Coronavirus SARS-CoV-2 infection, which may include but is not limited to Remdesivir (Veklury) or receiving convalescent plasma therapy for SARS-CoV-2; The subject is undergoing treatment currently or had undergone within the past fourteen (14) days of the study visit with RSV-related medication which may include but is not limited to Ribavirin (Virazole), RSV-IGIV (RespiGam) or palivizumab (Synagis). The subject is currently receiving or has received within the past thirty (30) days of the study visit an experimental biologic, drug, or device including either treatment or therapy. The subject has previously participated in this research study (CS-1262-01).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ramin Farsad
Organizational Affiliation
Diagnamics, Inc
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Sherri Casey
Organizational Affiliation
Benchmark Research
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Justin Wilson
Organizational Affiliation
Cullman Clinical Trials
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Miguel Perez
Organizational Affiliation
Excellence Medical and Research
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Mary Imig
Organizational Affiliation
Koch Family Medicine
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Marisela Gonzalez
Organizational Affiliation
Marisela Gonzalez, MD, PA
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Lawrence Gervasi
Organizational Affiliation
Clinical Research Solutions
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Rogelio Machuca
Organizational Affiliation
Machuca Foundation
Official's Role
Principal Investigator
Facility Information:
Facility Name
Cullman Clinical Trials
City
Cullman
State/Province
Alabama
ZIP/Postal Code
35055
Country
United States
Facility Name
Diagnamics, Inc
City
Encinitas
State/Province
California
ZIP/Postal Code
92024
Country
United States
Facility Name
Excellence Medical and Research
City
Miami Gardens
State/Province
Florida
ZIP/Postal Code
33169
Country
United States
Facility Name
Marisela Gonzalez, MD, PA
City
Miami
State/Province
Florida
ZIP/Postal Code
33155
Country
United States
Facility Name
Koch Family Medicine
City
Morton
State/Province
Illinois
ZIP/Postal Code
61550
Country
United States
Facility Name
Benchmark Research
City
Covington
State/Province
Louisiana
ZIP/Postal Code
70433
Country
United States
Facility Name
Machuca Foundation
City
Las Vegas
State/Province
Nevada
ZIP/Postal Code
89104
Country
United States
Facility Name
Clinical Research Solutions
City
Middleburg Heights
State/Province
Ohio
ZIP/Postal Code
44130
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Performance Evaluation of the LumiraDx SARS-CoV-2 & FLU A/B and SARS-CoV-2 & RSV Tests for Aid in the Assessment of COVID-19

We'll reach out to this number within 24 hrs